Format

Send to

Choose Destination
Asian Pac J Cancer Prev. 2018 Feb 26;19(2):387-393.

Ellagic Acid Holds Promise Against Hepatocellular Carcinoma in an Experimental Model: Mechanisms of Action

Author information

1
Zoology Department, Faculty of Women for Arts, Science and Education, Ain Shams University, Cairo, Egypt. Email: drazizanrc@yahoo.com

Abstract

This research work was initiated to explore the efficacy of ellagic acid in mitigation of hepatocarcinogenesis in rats. Rats were distributed into 4 groups; negative control, hepatocellular carcinoma (HCC), doxorubicin and ellagic acid. Serum alpha-fetoprotein (AFP), glypican-3 (GPC-3), signal transducer and activator of transcription 3 (STAT3) and suppressors of cytokine signaling 3 (SOCS3) levels were assayed by ELISA. Immunohistochemical examination of hepatic VEGF expression was also conducted, along with histological procedures for examination of liver tissue sections. Significant elevation in serum AFP, GPC-3 and STAT3 levels with a significant drop in SOCS3 were observed in the HCC group. In contrast, the treated groups showed significant decline in serum AFP, GPC-3 and STAT3 levels and significant increase in SOCS3. Additionally, the HCC group declared mild positive immunoreaction for VEGF in hepatocytes while treatment with doxorubicin or ellagic acid was associated with a negative immunoreaction for VEGF. These results were supported by histological examination of liver tissue. The obtained findings suggested that ellagic acid may have beneficial chemopreventive role against hepatocarcinogenesis through its apoptotic, antiangiogenic and antiproliferative activities.

KEYWORDS:

Hepatocellular carcinoma; N‚ąínitrosodiethylamine; ellagic acid; doxorubicin- rats

PMID:
29479987
PMCID:
PMC5980924
DOI:
10.22034/APJCP.2018.19.2.387
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Asian Pacific Organization for Cancer Prevention Icon for PubMed Central
Loading ...
Support Center